Cantor Fitzgerald Reiterates Overweight on AVITA Medical, Maintains $26 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on AVITA Medical (NASDAQ:RCEL) and maintained a $26 price target.
October 19, 2023 | 4:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on AVITA Medical and maintained a $26 price target, which could positively impact the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of an Overweight rating and a maintained price target by Cantor Fitzgerald suggests a positive outlook for AVITA Medical, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100